TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04520126

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olivomed (capsules containing hydroxytyrosol)
Description: patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olivomed (capsules containing hydroxytyrosol)
Description: patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olivomed (capsules containing hydroxytyrosol)
Description: patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olivomed (capsules containing hydroxytyrosol)
Description: patients with stable coronary artery disease will be randomised to Olivomed or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).
Description: patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).
Description: patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).
Description: patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: OlivomedSmart - Capsules containing - combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - (OL:HT:OC 2:1:3), (5 mg HT bid).
Description: patients with stable coronary artery disease will be randomised to combination of OL, HT, OC or placebo for one month and then they will be crossed over to the alternate treatment for one month.
Study: NCT04525937

Intervention type: OTHER
Intervention: Patient Questionnaire
Description: Patient Questionnaire

Intervention type: OTHER
Intervention: Provider Questionnaire
Description: Provider Questionnaire
Study: NCT01666769

Intervention type: DRUG
Group type: OTHER
Intervention: Micafungin
Description: 4 mg/kg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Micafungin
Description: 8 mg/kg/day

Intervention type: DRUG
Group type: OTHER
Intervention: Micafungin
Description: Standard of care Dosing
Study: NCT02452437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Controlled release oxycodone 40 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Controlled release oxycodone 40 mg twice daily
Study: NCT01320891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balanced solutions
Description: during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: not balanced
Description: during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
Study: NCT05300750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral fluids
Description: Starting amount of oral fluid after 2 hours post C/s should be 5cm and then increase gradually to be 45-50 cm of oral fluid at 4 hours post C/s and 100 cm each hours later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Chewed free sugar gum for 15 minutes
Study: NCT02720497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 60-minute Prolonged Exposure Therapy
Description: This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 90-minute Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
Study: NCT02554162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye products with varying structures
Description: The satiating effect of rye products with various structures will be studied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye products with varying structures
Description: The satiating effect of rye products with various structures will be studied
Study: NCT00799838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d
Study: NCT02554162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye products with varying structures
Description: The satiating effect of rye products with various structures will be studied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye products with varying structures
Description: The satiating effect of rye products with various structures will be studied

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rye products with varying structures
Description: The satiating effect of rye products with various structures will be studied
Study: NCT01495078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses.
Study: NCT02423629

Intervention type: DEVICE
Group type: OTHER
Intervention: Agili-C™ implantation procedure
Description: Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
Study: NCT00251121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-invasive electrophysiological study
Description: Transvenous pacing in right heart atrium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Description: Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
Study: NCT01252277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza™
Description: 4 capsules daily for 6 months
Study: NCT02965937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Story-centred care intervention program
Description: Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health consultation control condition
Description: The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
Study: NCT00549432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TALENT Enhanced LPS Endoluminal Stent-Graft System
Description: roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
Study: NCT00612092

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spiral image acquisition
Description: standard spiral scan protocol

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: sequential image acquisition
Description: sequential CT scan protocol
Study: NCT00534456

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
Study: NCT01756430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol SR 32mg, QD
Description: * Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
Study: NCT03053869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzodiazepine - limited use strategy
Description: 1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzodiazepine - Ad libitum strategy
Description: 1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy).
Study: NCT03238118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attention bias modification training
Description: Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Training
Description: Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
Study: NCT03189966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transversalis fascia plane block
Description: With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block
Description: The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 0.8 ml/Kg of ropivacaine 0.3%was injected.
Study: NCT01194622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine, Fluticasone
Description: TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone mono
Description: REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
Study: NCT02519569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy
Description: The intervention consists of ten writing assignments
Study: NCT01224444

Intervention type: OTHER
Intervention: standard polypectomy snare
Description: Electrocautery snare resection of sessile colonic polyps
Study: NCT04029571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM-FMD
Description: Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FMD
Description: A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD.
Study: NCT01442805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure Therapy
Description: Participants are exposed to the feared situation (flying) through the virtual reality technology

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy through Imagination
Description: Participants are exposed to the feared situation (flying) through exposure technique of imagination.
Study: NCT03083184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
Study: NCT00655785

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1-1084, VEGFR2-169
Description: One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
Study: NCT04209322

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed Radiofrequency
Description: Non-surgical treatment of lumbar disc herniation causing sciatica using pulsed radiofrequency (10 minutes) directed to the interested dorsal root ganglia (percutaneous technique); after radiofrequency application, using the same needle, steroid was administered (as per the control arm). The procedure was guided by CT imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection
Description: Percutaneous injection of steroid in the nerve root foramen. The procedure was guided by CT imaging
Study: NCT03083184

Intervention type: DRUG
Group type: OTHER
Intervention: enoxaparin
Description: An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
Study: NCT01756430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol SR 64mg, QD
Description: * Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol IR 25mg, QD
Description: * Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol IR 25mg, BID
Description: * Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks.
Study: NCT02441725

Intervention type: OTHER
Group type: OTHER
Intervention: 1-minute sit-to-stand test
Description: Validation of the 1-minute sit-to-stand test in a COPD patient population
Study: NCT01439178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Avastin injection
Description: Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Avastin injection
Description: Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
Study: NCT01756443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine/adrenaline and 0.5% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine/adrenaline and 0.5% bupivacaine
Study: NCT02196480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-TNF
Description: Anti-tumor necrosis factor therapy
Study: NCT01445704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05.
Study: NCT02182271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 ZW - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04386876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet
Description: Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).
Study: NCT01445704

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
Study: NCT03709511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: perioperative rehabilitation consists of education, inspiratory muscle training, active cycle of breathing techniques, and early mobilization.
Study: NCT05600673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution
Description: Topical Bimatoprost 0.03% solution

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 fractional laser
Description: CO2 fractional laser treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 fractional laser
Description: CO2 fractional laser treatment
Study: NCT04233424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-PLEX
Description: D-PLEX is a new formulation of extended release of Doxycycline. Each 5g D-PLEX vial contains 54.6mg Doxycycline free base (1.09%), which is equivalent to 63mg Doxycycline hyclate (1.26%). D-PLEX is supplied as a sterile powder to be reconstituted to paste in the operating room, using standard aseptic techniques and is intended for single administration. The non-active components of the extended release antibiotic formulation are β Tri-Calcium polymer and a lipid matrix. All formulation components are biodegradable.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: prophylactic, pre-operation per institution guidelines